SPAC Translational Development closes $172.5M IPO with full over-allotment

Translational Development Acquisition Corp.

IPO of 17.25M units at $10/unit raised $172.5M gross; units list on Nasdaq under TDACU.
Simultaneous private placement of 7.075M warrants at $1.00/warrant raised $7.075M from sponsor and underwriter.
Net proceeds of $174.225M placed in trust account; company has 18 months to complete a business combination.
Michael B. Hoffman named CEO/Chairman; Avanindra C. Das CFO; Board includes Reddy, Keith, Kestenbaum, Jarratt.
Directors appointed to audit, compensation, and nominating committees; indemnity agreements executed.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Translational Development Acquisition Corp.: Amended and restated memorandum and articles of association filed and effective (effective 2024-12-20).

Change: charter amendment
Effective: 2024-12-20

Exact text from the filing

On December 20, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on December 20, 2024.

View on SEC.gov

256 governance changes filed in the last 30 days. Browse all governance changes →

Translational Development Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-132134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.